Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17973442 | 0.86 | METAP2 (0.51) | METAP2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL7556102 | 0.86 | ACLY (0.62) | METAP2KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL2738122 | 0.85 | METAP2 (0.50) | METAP2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL22650327 | 0.84 | METAP2 (0.50) | METAP2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL16569780 | 0.83 | KDM4E (0.59) | METAP2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL12570805 | 0.82 | METAP2 (0.86) | METAP2CYP1A2CYP2C9ACLYMCL1 | |
| SCHEMBL31046886 | 0.81 | METAP2 (0.53) | METAP2KMT2AMEN1ALDH1A1MCL1 | |
| SCHEMBL30100431 | 0.81 | ACLY (0.66) | METAP2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL221627 | 0.81 | KMT2A (0.49) | METAP2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL221687 | 0.81 | METAP2 (0.53) | METAP2KMT2AMEN1ALDH1A1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207512-B | Tricyclic pyrazole simultaneously [1, the 5-A] pyrimidine derivatives that there is the piperidines of inhibitory activity to replace the duplication of Respiratory Syncytial Virus(RSV) (RSV) | 爱尔兰詹森科学公司 | 2019-09-10 | — | — | CN | disclosed |
| EP-2838900-B1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2838900-B1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10188754-B2 | Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-01-29 | — | — | US | disclosed |
| US-10174038-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174038-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3230288-B1 | PIPERIDINE SUBSTITUTED TRICYCLIC PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | JANSSEN SCIENCES IRELAND UC (IE) | 2018-11-21 | — | — | EP | disclosed |
| US-10131673-B2 | Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) | JANSSEN SCIENCES IRELAND UC (IE) | 2018-11-20 | — | — | US | disclosed |
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2018-10-18 | — | — | US | disclosed |
| EP-3012258-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVE AS AN ANTIVIRAL AGENT | GILEAD SCIENCES INC (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-2013096681-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096681-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| EP-2585467-A1 | PYRAZOLO [1, 5 -A]PYRIMIDINES AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| CN-102958933-A | Pyrazolo [1,5-A ] pyrimidines as antiviral agents | GILEAD SCIENCES INC | 2013-03-06 | — | — | CN | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131673-B2 | Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) | PIR, ZC3HAV1, MAVS | METAP2 3565/4885KMT2A 3461/4885MEN1 4823/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | METAP2 1647/4885KMT2A 3648/4885MEN1 3578/4885 |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | METAP2 3034/4885KMT2A 3906/4885MEN1 3739/4885 |
| US-10188754-B2 | Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) | GART, SLC43A1, AADAT | METAP2 3166/4885KMT2A 904/4885MEN1 2520/4885 |
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | METAP2 1647/4885KMT2A 3648/4885MEN1 3578/4885 |
| US-10174038-B2 | Compounds and methods for antiviral treatment | ZC3HAV1, SARS1, MAVS | METAP2 622/4885KMT2A 3849/4885MEN1 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.